GlassScriptPhysician profile
Nzisa Mutinga
NPI 1104891837
$5,990.83
in general payments reported to CMS, 2019-2025
31 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $593 · 2020: $298 · 2021: $567 · 2022: $754 · 2023: $1,284 · 2024: $1,413 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,702 · Education: $76.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,702.07 |
| Education | $76.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $658.97 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $596.17 | 2019-2025 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $563.40 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $524.00 | 2019-2025 | Velphoro, Velphoro |
| Calliditas Therapeutics US INC. | $491.83 | 2022-2025 | Tarpeyo |
| Amgen INC. | $466.68 | 2019-2025 | Tavneos, Krystexxa |
| Vifor Pharma, INC. | $379.38 | 2019-2025 | Veltassa |
| Aurinia Pharma U.S., INC. | $269.30 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $246.99 | 2021-2025 | |
| Travere Therapeutics, INC. | $234.28 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $199.74 | 2020-2025 | Acthar, Terlivaz |
| Akebia Therapeutics INC | $187.20 | 2019-2024 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $182.51 | 2019-2023 | Rayaldee |
| Glaxosmithkline, LLC. | $160.04 | 2021-2024 | Benlysta, Jesduvroq |
| Alexion Pharmaceuticals, INC. | $146.06 | 2019-2024 | Ultomiris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $107.87 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $85.40 | 2019-2023 | |
| Daiichi Sankyo INC. | $83.88 | 2019-2024 | Injectafer |
| Ardelyx, INC. | $71.60 | 2023-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $66.92 | 2021-2023 | Onpattro |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $52.74 | 2025 | |
| Lilly USA, LLC | $43.82 | 2023-2024 | Jardiance |
| Cormedix INC. | $27.47 | 2024 | Defencath |
| Mallinckrodt Enterprises LLC | $23.59 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.39 | 2022 | |
| Cvrx, INC. | $20.81 | 2024 | Barostim Neo System |
| Pharmacosmos Therapeutics INC. | $15.93 | 2022 | |
| Recordati_rare_diseases_inc. | $15.76 | 2021 | |
| Lundbeck LLC | $15.69 | 2019 | |
| Kyowa Kirin, INC. | $15.26 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nzisa Mutinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.